Literature DB >> 21893034

Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer.

Naoko Okumura1, Hitomi Yoshida, Yasuko Kitagishi, Yuri Nishimura, Satoru Matsuda.   

Abstract

Alternative splicing is a major contributor to transcriptome and proteome diversity, which can lead to the deregulation of crucial cellular processes and have been associated with a variety of human diseases including cancer. As p53, BRCA1, and PTEN proteins have a key role in preventing breast cancer formation, cancer-associated splicing variants of these tumor suppressor genes are potential molecular markers and may contribute to the development of diagnostic and prognostic methods. In the present review, we summarize these tumor suppressor genes at a viewpoint of alternative splicing involved in breast cancer.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21893034     DOI: 10.1016/j.bbrc.2011.08.098

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  33 in total

1.  BRCA1 exon 11 a model of long exon splicing regulation.

Authors:  Michela Raponi; Lindsay D Smith; Marco Silipo; Cristiana Stuani; Emanuele Buratti; Diana Baralle
Journal:  RNA Biol       Date:  2014-03-18       Impact factor: 4.652

2.  Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner.

Authors:  Begüm Kocatürk; Yascha W Van den Berg; Chris Tieken; J Sven D Mieog; Esther M de Kruijf; Charla C Engels; Martijn A van der Ent; Peter J Kuppen; Cornelis J Van de Velde; Wolfram Ruf; Pieter H Reitsma; Susanne Osanto; Gerrit-Jan Liefers; Vladimir Y Bogdanov; Henri H Versteeg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-25       Impact factor: 11.205

Review 3.  Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.

Authors:  Nidhi Jyotsana; Michael Heuser
Journal:  Expert Opin Ther Targets       Date:  2017-12-20       Impact factor: 6.902

Review 4.  BRCA1-No Matter How You Splice It.

Authors:  Dan Li; Lisa M Harlan-Williams; Easwari Kumaraswamy; Roy A Jensen
Journal:  Cancer Res       Date:  2019-04-16       Impact factor: 12.701

Review 5.  Mechanisms of cancer cell killing by metformin: a review on different cell death pathways.

Authors:  Xiao-Yu Wu; Wen-Wen Xu; Xiang-Kun Huan; Guan-Nan Wu; Gang Li; Yu-Hong Zhou; Masoud Najafi
Journal:  Mol Cell Biochem       Date:  2022-06-30       Impact factor: 3.396

Review 6.  Alternative RNA splicing and cancer.

Authors:  Sali Liu; Chonghui Cheng
Journal:  Wiley Interdiscip Rev RNA       Date:  2013-06-13       Impact factor: 9.957

7.  GT198 Splice Variants Display Dominant-Negative Activities and Are Induced by Inactivating Mutations.

Authors:  Min Peng; Zheqiong Yang; Hao Zhang; Lahcen Jaafar; Guanghu Wang; Min Liu; Hernan Flores-Rozas; Jianming Xu; Nahid F Mivechi; Lan Ko
Journal:  Genes Cancer       Date:  2013-01

8.  MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.

Authors:  Zhigang Xie; Jing Yuan Chooi; Sabrina Hui Min Toh; Dongxiao Yang; Nurhidayah Binte Basri; Ying Swan Ho; Wee Joo Chng
Journal:  Leukemia       Date:  2018-11-23       Impact factor: 11.528

9.  Alternative splicing and its impact as a cancer diagnostic marker.

Authors:  Yun-Ji Kim; Heui-Soo Kim
Journal:  Genomics Inform       Date:  2012-06-30

10.  RNA sequencing of cancer reveals novel splicing alterations.

Authors:  Jeyanthy Eswaran; Anelia Horvath; Sucheta Godbole; Sirigiri Divijendra Reddy; Prakriti Mudvari; Kazufumi Ohshiro; Dinesh Cyanam; Sujit Nair; Suzanne A W Fuqua; Kornelia Polyak; Liliana D Florea; Rakesh Kumar
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.